Resources

A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv.

How are pharmaceutical companies, policymakers and investors seeking growth amid fast-changing international politics, trade deals, a looming patent cliff, and technological innovation? Our maiden Life sciences and healthcare insights report offers a global perspective on disruptive forces from artificial intelligence to regulatory shifts.

Complement Therapeutics receives FDA IND clearance to advance its lead gene therapy CTx001 into Opti-GAIN, a Phase I/II clinical trial in Geographic Atrophy secondary to AMD

Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing.

VectorBuilder wins two IMAPAC awards, cementing leadership in gene therapy and CDMO innovation

The Life Sciences Learner Hub – the evolution of the proven ATSTN Online Training Platform, now expanded to serve the broader life sciences community.

Darren Blamire, Autolus, and Diana Hernandez, Anthony Nolan, will steer BIA’s Cell and Gene Therapy Advisory Committee, driving UK leadership and patient access in this transformative field.

Poolbeg Pharma plc, headquartered in London and listed on AIM, is running a UK-based clinical trial of POLB 001 to test its ability to prevent cancer immunotherapy-induced cytokine release syndrome (CRS)—a major bottleneck to the wider rollout of breakthrough cancer immunotherapies.

In this blog, Alan Griffith, Head of CDMO Global Operations, shares their achievements, priorities, and ambitions as a new member of the BIA community.

Cell and Gene Therapy Catapult (CGT Catapult), is working with VascVersa to develop a test that predicts the clinical efficacy of its experimental cell therapy for ischaemic diseases. This test will be used as a qualified assay as part of the cell manufacturing process.

The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit.

Pioneer Group has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.

Pharmaron is thrilled to announce the successful completion of Phase One in the major expansion of our Liverpool Gene Therapy and Biologics CDMO site!

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has announced a new strategic partnership with Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS), the experts in cellular starting materials providing donor material solutions to the cell and gene therapy industry.

PHARMExcel is celebrating recognition of TOP UK CRO wholeheartedly as an acknowledgement of its efforts to create a distinctive niche in the Contract Research Organisation (CRO) industry, one which balances the commercial and scientific objectives of the biotech/researcher with the practical clinical trial delivery challenges and positive patient outcomes.

CGT Catapult, an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Jim Faulkner as its new Chairman, effective from 29th July 2025.

Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Ed Samuel as its Chief Operations Officer (COO).